Assessing biomarkers in a real-world severe asthma study (ARIETTA)

The prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 s controller medication are to be included.

Source: Respiratory Medicine CME - April 13, 2016 Category: Respiratory Medicine Authors: Roland Buhl, Stephanie Korn, Andrew Menzies-Gow, Michel Aubier, Kenneth R. Chapman, Giorgio W. Canonica, César Picado, Nicolas Martin, Ramon Aguiar Escobar, Stephan Korom, Nicola A. Hanania Source Type: research